We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




China's Anti-Doping Agency Prepares for Olympic Games

By Labmedica staff writers
Posted on 05 Jun 2008
The China Anti-Doping Agency (Beijing, China) will examine more than 4,500 samples from athletes for banned drugs during the 2008 Olympic Games.

Three leadership delegations so far from the Chinese agency have been hosted by Agilent Technologies Inc. More...
The meetings include technical training on anti-doping instruments and methods developed by Agilent (Santa Clara, CA, USA), a primary supplier of technology to China's Anti-Doping Agency since 1988.

The agency has equipped its Beijing lab with Agilent liquid chromatography (LC), gas chromatography (GC), and mass spectrometry (MS) instruments to confirm the chemical identity of suspected banned substances found in testing samples. Agilent is providing 18 LC/MS units and 19 GC/MS units for drug testing at the Games.

"China has quickly become a world model for anti-doping efforts,” said Du Lijun, director of China's Anti-Doping Agency. "Agilent's liquid chromatography and mass spectrometry instrumentation will help make China's Anti-Doping Agency testing in the 2008 Olympic Games the most technologically advanced yet.”


Related Links:
China Anti-Doping Agency
Agilent

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Repetitive Pipette
VWR® Stepper Pro
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.